Truist Reduces Price Target for PROCEPT BioRobotics Corporation (PRCT) to $50 from $64, Maintains Buy Rating
Price Target Adjustment: Truist has reduced the price target for PROCEPT BioRobotics Corporation (NASDAQ:PRCT) from $64 to $50 while maintaining a Buy rating, anticipating healthy Q3 earnings but also potential stock volatility.
Company Overview: PROCEPT BioRobotics is a surgical robotics company focused on urology, known for its AquaBeam Robotic System, which is used in minimally invasive surgeries. Despite its potential, some analysts suggest that certain AI stocks may offer better investment opportunities.
Get Free Real-Time Notifications for Any Stock
Analyst Views on PRCT
About PRCT
About the author
PRCT Options Analysis: Put Contract Offers 4.4% YieldBoost Potential
- Put Contract Yield: The $25.00 put contract for PRCT has a current bid of $1.10, and if an investor sells to open this contract, they commit to buying shares at $25.00, resulting in a cost basis of $23.90, which represents a 17% discount compared to the current price of $30.29, making it attractive for potential buyers.
- Expiration Risk Analysis: Current data suggests a 79% chance that the put contract will expire worthless, which would yield a 4.40% return on the cash commitment, or an annualized yield of 27.71%, referred to as YieldBoost, highlighting the contract's appeal.
- Call Contract Returns: The $32.50 call contract for PRCT has a current bid of $2.00, and if an investor buys shares at $30.29 and sells this contract, they could achieve a total return of 13.90% if the stock is called away at expiration, showcasing the potential profitability of this strategy.
- Volatility Comparison: The implied volatility for the put contract is 74%, while for the call contract it is 81%, compared to an actual trailing twelve-month volatility of 54%, indicating a high market expectation for future price fluctuations in PRCT stock, necessitating careful risk assessment by investors.
ETFs on the Move This Monday: REMX, IHI
ETF Performance: The iShares U.S. Medical Devices ETF is underperforming, down approximately 1.7% in Monday afternoon trading.
Weakest Components: Notable declines among ETF components include Axogen, which fell by about 4.9%, and Procept Biorobotics, down by about 4.2%.
Market Context: The article provides insights into the performance of specific ETFs and their components, reflecting broader market trends.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
